Visium Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Visium Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-7,900	Closed	-$832K	–	608
2015 Q3	$832K	Buy	+7,900	New	+$1.06M	0.01%	523
2015 Q2	–	Sell	-584,503	Closed	-$72.8M	–	1143
2015 Q1	$72.8M	Sell	584,503 -403,888	-41%	-$42.8M	1.07%	12
2014 Q4	$89.4M	Buy	+988,391	New	+$82.2M	1.26%	8

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's BMRN Position: Q4 2015 in Review

Visium Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 7,900 shares — an estimated $832K sold.

Visium Asset Management first reported a position in BMRN in Q4 2014 and held it in 3 quarters. The position peaked at $89.4M in Q4 2014. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Visium Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Visium Asset Management sold 7,900 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $832K.
Visium Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 3 quarters.
Visium Asset Management's BioMarin Pharmaceuticals position peaked at $89.4M in Q4 2014.
388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.